New alkyl cationic glycerolipids with heterocyclic polar domain are responsible for disorders in the leukemia cells cycle and cells apoptosis

A series of new modifications of alkyl cationic glycerolipids with hetero polar domain has been synthesized. The most active compound rac-N-(4-[(2-ethoxy-3-octadecyloxy)prop-1-yloxycarbonyl]butyl)-N'-etylimidazoliyiodid in micromolar concentrations causes a delay of cell cycle in phase G1, DNA...

Full description

Saved in:
Bibliographic Details
Published inBioorganicheskaia khimiia Vol. 36; no. 4; p. 574
Main Authors Markova, A A, Pliavnik, N V, Tatarskiĭ, Jr, V V, Shtil', A A, Serebrennikova, G A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.07.2010
Subjects
Apoptosis - drug effects
DNA Fragmentation - drug effects
G1 Phase - drug effects
Glycerides - chemical synthesis
Glycerides - chemistry
Glycerides - pharmacology
Heterocyclic Compounds - chemical synthesis
Heterocyclic Compounds - chemistry
Heterocyclic Compounds - pharmacology
Humans
K562 Cells
Leukemia - drug therapy
Leukemia - metabolism
Online AccessGet more information

Cover

More Information
Summary:A series of new modifications of alkyl cationic glycerolipids with hetero polar domain has been synthesized. The most active compound rac-N-(4-[(2-ethoxy-3-octadecyloxy)prop-1-yloxycarbonyl]butyl)-N'-etylimidazoliyiodid in micromolar concentrations causes a delay of cell cycle in phase G1, DNA fragmentation and apoptosis of cell line leukemia.
ISSN:0132-3423